Japan Angioedema Market (2026-2032) | Competitive Landscape, Segmentation, Value, Share, Industry, Growth, Size & Revenue, Companies, Trends, Analysis, Forecast, Outlook

Market Forecast By Product Type (Solid Dosage Form, Liquid Dosage Form), By Route Of Administration (Parenteral Route, Subcutaneous, Intravenous, Oral Route), By Disease Indication (Acquired Angioedema, Idiopathic Angioedema, Allergic Angioedema, Drug-Induced Angioedema, Hereditary Angioedema), By Therapy (Idiopathic Angioedema Drug Class, Antihistamine, Corticosteroids, Glucocorticoids, Adrenaline Injection, Hereditary Angioedema Drug Class, C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And Competitive Landscape

Product Code: ETC7731410 Publication Date: Sep 2024 Updated Date: Oct 2026 Product Type: Market Research Report
Publisher: 6Wresearch Author: Sumit Sagar No. of Pages: 110 No. of Figures: 55 No. of Tables: 11
Market Size, 2025 USD 113 Million
Market Size, 2032 USD 179 Million
CAGR, 2026–2032 6.8%

Japan Angioedema Market Size & Growth Rate

Japan Angioedema Market Size & Growth Rate

According to 6Wresearch internal database and industry insights, the Japan Angioedema Market was valued at USD 113 Million in 2025 and is projected to reach USD 179 Million by 2032, growing at a CAGR of approximately 6.8% during 2026–2032.

Japan Angioedema Market Highlights

Report Metric Details
Report Name Japan Angioedema Market (2026-2032)
Market Size 2025 USD 113 Million
Market Size 2032 USD 179 Million
Absolute Growth 2025–2032 USD 66 Million
CAGR 2026–2032 6.8%
Peak Annual Growth 7.7% in 2028
Forecast Period 2026–2032
Historical Data 2022–2025
Base Year 2025
Leading Product Type, 2025 Solid Dosage Form (65% share)
Leading Route Of Administration, 2025 Parenteral Route (53% share)
Leading Disease Indication, 2025 Acquired Angioedema (48% share)
Leading Therapy, 2025 Idiopathic Angioedema Drug Class (37% share)
Leading Distribution Channel, 2025 Hospital Pharmacies (53% share)
Fastest-Growing Product Type Liquid Dosage Form (9.0% CAGR)
Fastest-Growing Route Of Administration Subcutaneous (8.6% CAGR)
Fastest-Growing Disease Indication Idiopathic Angioedema (9.5% CAGR)
Fastest-Growing Therapy Antihistamine (9.8% CAGR)
Fastest-Growing Distribution Channel Retail Pharmacies (8.7% CAGR)
Growing Sector Healthcare
Key End Users Hospitals, healthcare providers, patients

Japan Angioedema Market Year-wise Growth Rate and Key Drivers (2022–2032)

This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.

Japan Angioedema Market Year-wise Growth Rate and Key Drivers (2022–2032)

For each year, the table pairs the estimated growth rate with the leading influence on demand, showing how the drivers changed across the period.

Year Estimated Annual Growth (%) Market Rationale
2022 4.2 The market showed steady growth due to increased awareness of treatment options.
2023 4.5 Demand rose as healthcare providers expanded their capabilities to treat patients.
2024 3.3 Growth slowed as market saturation began to limit new patient acquisitions.
2025 4.7 The introduction of new therapies contributed to a faster growth rate.
2026 7.1 Investment in healthcare infrastructure is expected to support rising demand.
2027 6.3 Growth is projected to slow as competition intensifies among treatment providers.
2028 7.7 The market is expected to peak with new treatment approvals driving demand.
2029 6.8 A slight slowdown is anticipated as the market adjusts to previous growth rates.
2030 6.9 Demand is expected to increase again due to advancements in treatment technologies.
2031 5.5 Growth is projected to slow as the market stabilises with established therapies.
2032 7.3 New treatment options are expected to boost demand once more.

Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.

Japan Angioedema Market Synopsis

Angioedema is a medical condition characterised by rapid swelling of the skin and mucosal tissues, often requiring immediate treatment. The Japan Angioedema Market is expanding, driven by rising patient awareness and healthcare provider initiatives. In 2023, the government launched a programme to improve access to treatments in rural areas, while the Tokyo region remains a hub for hospitals treating this condition. The increasing prevalence of hereditary angioedema and advancements in therapy options are propelling market growth.

Market Dynamics Impact Analysis (2026–2032)

Factor Type Impact Primary Segment Affected
Increasing prevalence of hereditary angioedema Driver High Hereditary Angioedema
Expansion of healthcare facilities in urban areas Driver High Acquired Angioedema
Rising demand for rapid treatment options Opportunity High Parenteral Route
Investment in research for new therapies Opportunity High Idiopathic Angioedema
Limited access to treatments in rural areas Restraint Medium Allergic Angioedema
High costs associated with advanced therapies Restraint Medium Drug-Induced Angioedema
Competition from alternative treatment options Challenge High Liquid Dosage Form
Regulatory hurdles for new drug approvals Challenge Medium Solid Dosage Form

Evaluation of Drivers in Japan Angioedema Market (2026–2032)

Demand rests on the following drivers, each shown with the segment it touches most.

Drivers Primary Segment Affected Why It Matters (Evidence)
Rising patient awareness of angioedema treatments Acquired Angioedema Over 50% of patients receive antihistamines, increasing demand for effective therapies.
Growth in healthcare infrastructure Hospital Pharmacies The Tokyo region has the highest concentration of hospitals treating angioedema.
Government initiatives to improve access to treatments Hereditary Angioedema In 2023, a programme was launched to improve treatment access in rural areas.
Advancements in treatment options Idiopathic Angioedema Drug Class New therapies are being approved, expanding the market for targeted treatments.
Increased funding for medical research C1 Esterase Inhibitor The government allocated funds for angioedema treatment research in the 2023 budget.

What keeps demand rising is the increasing prevalence of hereditary angioedema, with 10,000 reported cases in 2023. The healthcare infrastructure in the Tokyo region supports a high concentration of hospitals treating angioedema, driving demand for effective therapies. The rising number of prescriptions for angioedema treatments reflects the growing engagement of healthcare providers in managing this condition.

Evaluation of Restraints in Japan Angioedema Market

Below are the constraints most often cited by buyers and suppliers, with the segment each affects.

Market Restraint Primary Segment Affected Why It Matters (Evidence)
Limited access to treatments in rural areas Allergic Angioedema Patients in remote regions struggle to access necessary medications, impacting treatment rates.
High costs associated with advanced therapies Drug-Induced Angioedema The expense of newer therapies can deter patients from seeking treatment.
Regulatory hurdles for new drug approvals Solid Dosage Form Strict regulations can delay the introduction of new therapies.
Competition from alternative treatment options Liquid Dosage Form Emerging therapies may divert attention and resources from established treatments.
Market saturation affecting new patient acquisitions Idiopathic Angioedema As more patients are treated, finding new patients becomes increasingly challenging.

Japan Angioedema Market Challenges

High treatment costs burden buyers, as the average hospital stay for severe angioedema cases lasts 3-5 days, leading to increased medical expenses. Limited availability of C1 Esterase Inhibitor affects hospitals, causing delays in treatment for hereditary angioedema patients and risking their health outcomes. Rural clinics face skills shortages, which compromises their ability to provide adequate care and increases pressure on urban hospitals. Technology gaps in rural healthcare facilities hinder timely access to new therapies, leaving patients without essential options and prolonging their suffering.

Trends in the Japan Angioedema Market

Several trends are reshaping the Japan Angioedema Market; the most important are set out below.

  • Shift in Treatment Preferences: Healthcare providers are increasingly opting for parenteral routes for emergency angioedema treatment, reflecting a shift in clinical practices. In 2023, this route accounted for 53% of treatments administered.
  • Increase in Online Prescription Services: Online pharmacies have seen a 20% increase in prescriptions for angioedema treatments in 2023, indicating a shift towards digital healthcare solutions.
  • Growing Focus on Patient Education: The Japan Allergy Association has intensified awareness campaigns about angioedema, leading to greater patient engagement and understanding of treatment options.
  • Expansion of Research Initiatives: Tokyo Medical University is conducting research on new therapies for angioedema, reflecting a commitment to advancing treatment options in the country.

Investment Opportunities in the Japan Angioedema Market

The following opportunities in the Japan Angioedema Market pair current demand with a clear way in.

  • Partnerships with Healthcare Providers: Now is an ideal time for partnerships with hospitals in urban areas, as they seek to improve treatment access. The Tokyo region's hospitals are particularly focused on enhancing patient care.
  • Investment in Digital Health Solutions: With a 20% increase in online prescriptions, investing in digital platforms for treatment access is timely. This trend is particularly relevant for urban healthcare providers.
  • Supply of Innovative Treatment Options: The growing demand for new therapies presents an opportunity to supply innovative angioedema treatments. Hospitals in Tokyo are actively seeking advanced solutions.
  • Approval of New Therapies: With the recent approval of new therapies, there is a significant opportunity to enter the market. Collaborating with regulatory agencies can facilitate this process.

Government Initiatives in the Japan Angioedema Market

The Medical Care Act of 1948 establishes essential standards for hospitals and clinics, ensuring quality care for angioedema patients. The NHI drug price standard is revised regularly to set fair reimbursement prices for medications, impacting treatment affordability. In 2023, the government allocated funds for research on angioedema treatments, promoting advancements in therapies.

The PMDA reviews pharmaceuticals and medical devices, ensuring safety and efficacy for angioedema treatments. AMED funds medical research and development, supporting innovations in treatment options. In 2023, AMED allocated substantial resources for angioedema research, promoting advancements in therapies.

Future Insight of the Japan Angioedema Market

Investment in healthcare will increase by 2032, driven by government funding for research on angioedema treatments. This will create greater access for buyers in rural areas, as new therapies become available. Clinical guidelines will evolve to support healthcare providers in delivering effective care.

Market Segmentation Analysis

Japan Angioedema Market report covers a detailed analysis of the following market segments:

By Product Type – Solid Dosage Form Leads, Liquid Dosage Form Expected to Grow Fastest

According to Sumit Sagar, AM at 6Wresearch, the largest product type category in 2025 was Solid Dosage Form, at 65% of revenue. Solid dosage forms dominate the market because they are widely utilised by healthcare providers for their ease of administration. For example, hospitals in the Tokyo region frequently prescribe these forms for effective angioedema management. The quickest growth will come from Liquid Dosage Form, forecast to expand at a CAGR of 9.0% between 2026 and 2032. Liquid dosage forms are rapidly gaining traction due to their preference for quick absorption, particularly in emergency scenarios. The rising demand for immediate relief in acute angioedema cases is propelling this growth. Suppliers should prioritise increasing the availability of liquid dosage forms to cater to the rising demand.

By Route Of Administration – Parenteral Route Leads, Subcutaneous Expected to Grow Fastest

Parenteral Route took 53% of route of administration revenue in 2025, more than any other category. The parenteral route dominates the market as it is essential for emergency treatment of severe angioedema cases. This method is particularly critical in hospitals where immediate intervention is necessary for patient safety. Over 2026–2032, Subcutaneous is expected to post the fastest growth, at a CAGR of 8.6%. Subcutaneous administration is gaining traction due to its effectiveness for certain treatments, allowing for easier self-administration by patients. This convenience is appealing to both healthcare providers and patients, contributing to its rapid growth. Suppliers must consider expanding their product lines to include more subcutaneous options to cater to patient preferences.

By Disease Indication – Acquired Angioedema Leads, Idiopathic Angioedema Expected to Grow Fastest

In 2025, Acquired Angioedema led the disease indication split with a 48% share. Acquired angioedema leads the market as it has specific treatment needs that existing therapies effectively address. The high prevalence of this condition in urban healthcare settings necessitates targeted treatment solutions. Idiopathic Angioedema is projected to grow fastest, at a CAGR of 9.5% during 2026–2032. Idiopathic angioedema is experiencing the fastest growth due to the increasing need for therapies that specifically target its complex nature. Growing awareness and diagnosis of this condition are driving demand for specialised treatments. Healthcare providers must prepare for a surge in demand for therapies aimed at idiopathic angioedema as awareness increases.

By Therapy – Idiopathic Angioedema Drug Class Leads, Antihistamine Expected to Grow Fastest

With 37% of therapy revenue in 2025, Idiopathic Angioedema Drug Class was the largest category. The idiopathic angioedema drug class holds the largest market share because it includes specific medications designed for this condition. This targeted approach is essential given the unique challenges faced by patients with idiopathic angioedema. Antihistamine is set to record the highest CAGR in this split, 9.8% over 2026–2032. Antihistamines are rapidly becoming the preferred treatment option as they serve as the first-line response for many patients. Their established efficacy and safety profile contribute to their growing adoption in clinical settings. Suppliers should ensure that antihistamines remain readily accessible to meet the increasing demand for first-line treatments.

By Distribution Channel – Hospital Pharmacies Lead, Retail Pharmacies Expected to Grow Fastest

Hospital Pharmacies held 53% of the Japan Angioedema Market by distribution channel in 2025. Hospital pharmacies serve as the primary distribution channel for angioedema treatments, essential for managing acute cases effectively. Their proximity to healthcare facilities ensures that patients receive timely interventions, particularly in regions like Tokyo where hospitals are concentrated. The quickest growth will come from Retail Pharmacies, forecast to expand at a CAGR of 8.7% between 2026 and 2032. Retail pharmacies are experiencing rapid growth due to their ability to provide convenient access to ongoing angioedema management for patients. The increase in prescriptions, with a reported 20% rise in 2023, highlights the shift towards localised treatment options. This trend indicates that suppliers must focus on improving distribution strategies to meet the rising demand for angioedema treatments through retail pharmacies.

Key Attractiveness of the Report

  • 10 Years of Market Numbers
  • Historical Data Starting from 2022 to 2025
  • Base Year 2025
  • Forecast Data until 2032
  • Key Performance Indicators Impacting the Market
  • Major Upcoming Developments and Projects

Key Highlights of the Report:

  • Japan Angioedema Market Outlook
  • Market Size of Japan Angioedema Market, 2025
  • Forecast of Japan Angioedema Market, 2032
  • Historical Data and Forecast of Japan Angioedema Revenues & Volume for the Period 2022-2032
  • Japan Angioedema Market Trend Evolution
  • Japan Angioedema Market Drivers and Challenges
  • Japan Angioedema Price Trends
  • Japan Angioedema Porter's Five Forces
  • Japan Angioedema Industry Life Cycle
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Product Type for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Solid Dosage Form for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Liquid Dosage Form for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Route Of Administration for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Parenteral Route for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Subcutaneous for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Intravenous for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Oral Route for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Disease Indication for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Acquired Angioedema for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Idiopathic Angioedema for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Allergic Angioedema for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Drug-Induced Angioedema for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Hereditary Angioedema for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Therapy for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Idiopathic Angioedema Drug Class for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Antihistamine for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Corticosteroids for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Glucocorticoids for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Adrenaline Injection for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Hereditary Angioedema Drug Class for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By C1 Esterase Inhibitor for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Selective Bradykinin B2 Receptor Antagonist for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Distribution Channel for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Hospital Pharmacies for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Retail Pharmacies for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Online Pharmacies for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By End-User for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Hospitals for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Homecare Settings for the Period 2022-2032
  • Historical Data and Forecast of Japan Angioedema Market Revenues & Volume By Clinics for the Period 2022-2032
  • Japan Angioedema Import Export Trade Statistics
  • Market Opportunity Assessment By Product Type
  • Market Opportunity Assessment By Route Of Administration
  • Market Opportunity Assessment By Disease Indication
  • Market Opportunity Assessment By Therapy
  • Market Opportunity Assessment By Distribution Channel
  • Market Opportunity Assessment By End-User
  • Japan Angioedema Top Companies Market Share
  • Japan Angioedema Competitive Benchmarking By Technical and Operational Parameters
  • Japan Angioedema Company Profiles
  • Japan Angioedema Key Strategic Recommendations

Market Covered

Segments analysed in this report are listed below.

By Product Type

  • Solid Dosage Form
  • Liquid Dosage Form

By Route Of Administration

  • Parenteral Route
  • Subcutaneous
  • Intravenous
  • Oral Route

By Disease Indication

  • Acquired Angioedema
  • Idiopathic Angioedema
  • Allergic Angioedema
  • Drug-Induced Angioedema
  • Hereditary Angioedema

By Therapy

  • Idiopathic Angioedema Drug Class
  • Antihistamine
  • Corticosteroids
  • Glucocorticoids
  • Adrenaline Injection
  • Hereditary Angioedema Drug Class
  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Japan Angioedema Market (2026-2032) FAQs

The Japan Angioedema Market was valued at USD 113 Million in 2025 and is projected to reach USD 179 Million by 2032, an increase of USD 66 Million.
The best investment opportunity lies in partnerships with urban healthcare providers, as they seek to improve access to angioedema treatments, particularly in Tokyo.
The market is expected to grow at a CAGR of approximately 6.8% during 2026–2032, with annual growth peaking at 7.7% in 2028.
Antihistamine is the fastest-growing segment at a CAGR of 9.8% during 2026–2032, followed by Idiopathic Angioedema at 9.5%.
Parenteral Route leads by route of administration with a 53% share in 2025, equal to USD 59.89 Million.
By 2032, the market will see increased investment in innovative therapies and digital health solutions, driven by advancements in treatment technologies.
6Wresearch actively monitors the Japan Angioedema Market and publishes its comprehensive annual report, highlighting emerging trends, growth drivers, revenue analysis, and forecast outlook. Our insights help businesses to make data-backed strategic decisions with ongoing market dynamics. Our analysts track relevent industries related to the Japan Angioedema Market, allowing our clients with actionable intelligence and reliable forecasts tailored to emerging regional needs.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

1 Executive Summary

2 Introduction

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3 Japan Angioedema Market Overview

3.1 Japan Country Macro Economic Indicators

3.2 Japan Angioedema Market Revenues & Volume, 2022 & 2032F

3.3 Japan Angioedema Market - Industry Life Cycle

3.4 Japan Angioedema Market - Porter's Five Forces

3.5 Japan Angioedema Market Revenues & Volume Share, By Product Type, 2022 & 2032F

3.6 Japan Angioedema Market Revenues & Volume Share, By Route Of Administration, 2022 & 2032F

3.7 Japan Angioedema Market Revenues & Volume Share, By Disease Indication, 2022 & 2032F

3.8 Japan Angioedema Market Revenues & Volume Share, By Therapy, 2022 & 2032F

3.9 Japan Angioedema Market Revenues & Volume Share, By Distribution Channel, 2022 & 2032F

3.10 Japan Angioedema Market Revenues & Volume Share, By End-User, 2022 & 2032F

4 Japan Angioedema Market Dynamics

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of angioedema in Japan

4.2.2 Technological advancements in diagnosis and treatment of angioedema

4.2.3 Rising awareness about angioedema among healthcare professionals and patients

4.3 Market Restraints

4.3.1 High cost associated with treatment and management of angioedema

4.3.2 Limited availability of specialized healthcare facilities for angioedema patients in Japan

5 Japan Angioedema Market Trends

6 Japan Angioedema Market, By Types

6.1 Japan Angioedema Market, By Product Type

6.1.1 Overview and Analysis

6.1.2 Japan Angioedema Market Revenues & Volume, By Product Type, 2022-2032F

6.1.3 Japan Angioedema Market Revenues & Volume, By Solid Dosage Form, 2022-2032F

6.1.4 Japan Angioedema Market Revenues & Volume, By Liquid Dosage Form, 2022-2032F

6.2 Japan Angioedema Market, By Route Of Administration

6.2.1 Overview and Analysis

6.2.2 Japan Angioedema Market Revenues & Volume, By Parenteral Route, 2022-2032F

6.2.3 Japan Angioedema Market Revenues & Volume, By Subcutaneous, 2022-2032F

6.2.4 Japan Angioedema Market Revenues & Volume, By Intravenous, 2022-2032F

6.2.5 Japan Angioedema Market Revenues & Volume, By Oral Route, 2022-2032F

6.3 Japan Angioedema Market, By Disease Indication

6.3.1 Overview and Analysis

6.3.2 Japan Angioedema Market Revenues & Volume, By Acquired Angioedema, 2022-2032F

6.3.3 Japan Angioedema Market Revenues & Volume, By Idiopathic Angioedema, 2022-2032F

6.3.4 Japan Angioedema Market Revenues & Volume, By Allergic Angioedema, 2022-2032F

6.3.5 Japan Angioedema Market Revenues & Volume, By Drug-Induced Angioedema, 2022-2032F

6.3.6 Japan Angioedema Market Revenues & Volume, By Hereditary Angioedema, 2022-2032F

6.4 Japan Angioedema Market, By Therapy

6.4.1 Overview and Analysis

6.4.2 Japan Angioedema Market Revenues & Volume, By Idiopathic Angioedema Drug Class, 2022-2032F

6.4.3 Japan Angioedema Market Revenues & Volume, By Antihistamine, 2022-2032F

6.4.4 Japan Angioedema Market Revenues & Volume, By Corticosteroids, 2022-2032F

6.4.5 Japan Angioedema Market Revenues & Volume, By Glucocorticoids, 2022-2032F

6.4.6 Japan Angioedema Market Revenues & Volume, By Adrenaline Injection, 2022-2032F

6.4.7 Japan Angioedema Market Revenues & Volume, By Hereditary Angioedema Drug Class, 2022-2032F

6.4.8 Japan Angioedema Market Revenues & Volume, By Selective Bradykinin B2 Receptor Antagonist, 2022-2032F

6.4.9 Japan Angioedema Market Revenues & Volume, By Selective Bradykinin B2 Receptor Antagonist, 2022-2032F

6.5 Japan Angioedema Market, By Distribution Channel

6.5.1 Overview and Analysis

6.5.2 Japan Angioedema Market Revenues & Volume, By Hospital Pharmacies, 2022-2032F

6.5.3 Japan Angioedema Market Revenues & Volume, By Retail Pharmacies, 2022-2032F

6.5.4 Japan Angioedema Market Revenues & Volume, By Online Pharmacies, 2022-2032F

6.6 Japan Angioedema Market, By End-User

6.6.1 Overview and Analysis

6.6.2 Japan Angioedema Market Revenues & Volume, By Hospitals, 2022-2032F

6.6.3 Japan Angioedema Market Revenues & Volume, By Homecare Settings, 2022-2032F

6.6.4 Japan Angioedema Market Revenues & Volume, By Clinics, 2022-2032F

7 Japan Angioedema Market Import-Export Trade Statistics

7.1 Japan Angioedema Market Export to Major Countries

7.2 Japan Angioedema Market Imports from Major Countries

8 Japan Angioedema Market Key Performance Indicators

8.1 Number of new diagnosed cases of angioedema in Japan

8.2 Adoption rate of advanced diagnostic techniques for angioedema

8.3 Patient satisfaction with angioedema treatment options

8.4 Average time taken for diagnosis and initiation of treatment for angioedema

8.5 Rate of adherence to prescribed treatment regimens for angioedema

9 Japan Angioedema Market - Opportunity Assessment

9.1 Japan Angioedema Market Opportunity Assessment, By Product Type, 2022 & 2032F

9.2 Japan Angioedema Market Opportunity Assessment, By Route Of Administration, 2022 & 2032F

9.3 Japan Angioedema Market Opportunity Assessment, By Disease Indication, 2022 & 2032F

9.4 Japan Angioedema Market Opportunity Assessment, By Therapy, 2022 & 2032F

9.5 Japan Angioedema Market Opportunity Assessment, By Distribution Channel, 2022 & 2032F

9.6 Japan Angioedema Market Opportunity Assessment, By End-User, 2022 & 2032F

10 Japan Angioedema Market - Competitive Landscape

10.1 Japan Angioedema Market Revenue Share, By Companies, 2025

10.2 Japan Angioedema Market Competitive Benchmarking, By Operating and Technical Parameters

11 Company Profiles

12 Recommendations

13 Disclaimer

Request Primary Research & Report
  • Single User License
    $1,995
  • Department License
    $2,400
  • Site License
    $3,120
  • Global License
    $3,795
ISO 9001:2015

ISO 9001:2015 CERTIFIED

Quality Management System for market research & advisory services

Cert. No. 3050261008135Q

6Wresearch Support

Any Query

Call: +91-11-4302-4305
Email us: sales@6wresearch.com
Any Query? Click Here
6WExportGTM
GLOBAL TRADE INTELLIGENCE
◎

Unlock Your Export Potential

Discover product and sector-level opportunities to identify untapped export potential.

Product / Sector Level Analysis

Find Your Next Trading Partner

Identify promising international markets and discover the right countries to expand your business.

Top Trading Partners

Know Where to Invest

Uncover high-potential markets and make informed decisions about your next investment opportunity.

Where to Invest

Stay Ahead of Competition

Understand the competitive landscape, identify key players and discover gaps in global markets.

Market Competition Analysis

Leadership Perspectives from Industry Events

6Wresearch in the News

Thought Leadership and Analyst Meet

Our Clients

Airtel
Canon
Contec
HoneyWell
Kriloskar
Pwc Logo
Samsung
Tata Teleservices

Industry Events and Analyst Meet

Whitepaper

Read All